Aniracetam Research Overview (also known as 1-p-anisoyl-2-pyrrolidinone, Ro 13-5057, Draganon)
Aniracetam is a synthetic, fat-soluble racetam compound investigated for effects on learning, memory, mood, and anxiety-related behavior. Its best-characterized molecular action is positive allosteric modulation of AMPA-type glutamate receptors, while preclinical evidence also suggests interactions with group I metabotropic glutamate receptors, including mGluR1 and mGluR5, and indirect effects on cholinergic, dopaminergic, and serotonergic signaling. Human evidence remains limited and mixed, and aniracetam is not an approved treatment for anxiety, depression, cognitive decline, or any other medical condition in many jurisdictions.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Aniracetam?
Aniracetam is a synthetic member of the racetam family of nootropic compounds. Its chemical name is commonly given as 1-p-anisoyl-2-pyrrolidinone, and it is also known by the development code Ro 13-5057. Like piracetam and several related compounds, aniracetam was developed as a research compound intended to influence learning and memory. It has attracted interest because laboratory and small clinical studies have reported possible effects on memory performance, anxiety-related behavior, mood, social interaction, and cognitive flexibility. These findings should be interpreted cautiously: much of the evidence comes from animal experiments, cell models, older clinical trials, or studies with methodological limitations, and aniracetam has not established efficacy comparable with approved psychiatric or neurological medicines.
Aniracetam is substantially more lipophilic, or fat-soluble, than piracetam. Oral absorption is variable and is generally improved when it is taken with a meal containing dietary fat. The parent compound is rapidly metabolized, particularly to N-anisoyl-GABA and other metabolites, and both the parent drug and metabolites may contribute to observed biological effects. Fat solubility does not automatically mean that the compound accumulates indefinitely in body tissues, but it does make meal timing, product formulation, metabolism, and individual differences relevant. Aniracetam is sold as a research chemical or supplement in some markets, while its legal status, quality controls, and permitted uses vary by country. Anyone considering use should verify local regulations and discuss potential risks with a qualified clinician, especially when taking prescription medicines or when pregnant, breastfeeding, or managing a neurological or psychiatric disorder.
Research Indications
Glutamatergic Signaling
AMPA receptor modulation
Preclinical electrophysiology studies indicate that aniracetam can positively modulate AMPA-type glutamate receptor signaling and prolong excitatory synaptic responses.
Synaptic plasticity models
Animal studies have examined facilitation of long-term potentiation and memory-related synaptic plasticity following aniracetam exposure.
Cognitive Performance
Memory impairment research
Small and older clinical studies evaluated aniracetam in cognitive impairment and dementia-related populations, with heterogeneous methods and outcomes.
Learning and recall tasks
Rodent behavioral studies commonly report effects on acquisition, retention, or reversal-learning tasks; translation to healthy human cognition remains uncertain.
Mood and Anxiety-Related Effects
Anxiolytic-like behavior
Preclinical work and metabolite research suggest possible serotonergic and cholinergic contributions to anxiety-related behavioral effects.
Subjective mood effects
Reports of improved sociability or mood are largely anecdotal; controlled evidence in healthy adults is limited.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Initial tolerance assessment | 250–500 mg | Once daily | Oral |
| Cognitive research protocols | 750 mg | 1–2 times daily | Oral |
| Older clinical-study range | 1,500 mg | Twice daily | Oral |
| Divided-dose research range | 1,500–3,000 mg/day | 2–3 divided doses | Oral |
Timing
Research use commonly places doses earlier in the day, often with food because aniracetam is lipophilic. Avoid late-day dosing if activation, headache, or sleep disruption occurs.
Peptide Interactions
Often paired in researcher communities; evidence for preventing headaches or improving outcomes from this combination is limited.
Mechanistically related racetam; combined use may increase adverse effects without established clinical benefit.
Concurrent stimulant exposure may increase insomnia, anxiety, irritability, headache, or cardiovascular symptoms in sensitive individuals.
Human interaction data are sparse; seek clinician review when combining with medicines that affect mood, serotonin, or seizure threshold.
Avoid using aniracetam to offset alcohol-related impairment; combined subjective effects are unpredictable and do not establish safety.
Do not combine without prescriber oversight, particularly where bleeding risk, surgery, or a history of hemorrhagic events is present.
Reported Research Timeline
01First dose to 2 hours (reported in cited studies): acute subjective effects, if present, may include alertness, mild stimulation, headache, nausea, or no noticeable change.
02Days 1–3 (reported in cited studies): assess sleep quality, anxiety, gastrointestinal tolerance, and headaches before considering any dose adjustment.
03Week 1 (reported in cited studies): any perceived effects on focus, verbal fluency, or mood should be tracked against baseline because expectancy effects can be substantial.
04Weeks 2–4 (reported in cited studies): use standardized cognitive or mood measures where possible; robust evidence for cumulative benefits in healthy adults is lacking.
05After 4 weeks (reported in cited studies): reassess continued use, adverse effects, concurrent medications, and whether measurable benefit justifies ongoing exposure.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Human safety data are limited, and much of the literature is older or based on populations with cognitive impairment rather than healthy adults.
Reported adverse effects can include headache, nervousness, insomnia, dizziness, nausea, and gastrointestinal discomfort.
Avoid use during pregnancy or breastfeeding because adequate safety data are unavailable.
People with seizure disorders, bipolar-spectrum illness, significant anxiety, liver disease, or kidney disease should obtain clinician guidance before use.
Do not drive or operate hazardous equipment until individual effects are known, particularly when starting or changing dose.
Seek Medical Attention If:
You develop chest pain, fainting, severe palpitations, or marked shortness of breath.
You experience facial swelling, hives, wheezing, or other signs of a serious allergic reaction.
You develop severe agitation, confusion, mania-like symptoms, or suicidal thoughts.
You have a seizure, unusual bleeding, or a severe persistent headache with neurologic symptoms.
Quality Indicators
Verified Marker
Batch-specific certificate of analysis
Request a current COA that identifies the lot number, test date, analyte identity, and quantitative purity result.
Verified Marker
HPLC or LC-MS identity and purity testing
Prefer third-party chromatographic testing documenting aniracetam identity and a stated purity specification rather than an unverified vendor claim.
Verified Marker
Contaminant screening
Look for independent heavy-metal and microbiological testing, especially for powders repackaged into capsules.
Acceptable Range
Capsule weight and labeled milligrams
A reputable label should clearly state aniracetam milligrams per capsule, serving size, excipients, and the manufacturer or responsible distributor.
Quality Concern
Missing documentation or implausible claims
Avoid products without lot-specific testing, with undisclosed proprietary blends, or with therapeutic claims that exceed available evidence.
Research Citations
- Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam.
Ito, I., Tanabe, S., Kohda, A., et al., 1990, The Journal of Physiology - The effects of aniracetam on excitatory synaptic currents in rat hippocampal neurons.
Tang, C. M., Shi, Q. Y., Katchman, A. N., et al., 1991, Neuroscience Letters - Piracetam and other structurally related nootropics.
Gouliaev, A. H., Senning, A., 1994, Brain Research Reviews - Aniracetam and its metabolites improve cognitive performance and affect neurotransmitter systems in experimental models.
Bartolini, L., Casamenti, F., Pepeu, G., et al., 1998, Neuropharmacology
Research Focus
anxiety, mood, memory, AMPA modulation, social cognition, creativity
Frequently Asked Questions
What should researchers watch for with Aniracetam?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Aniracetam?
First dose to 2 hours (reported in cited studies): acute subjective effects, if present, may include alertness, mild stimulation, headache, nausea, or no noticeable change.
How is Aniracetam typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →